Murphy Middleton Hinkle & Parker’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.5M Hold
3,750
1.83% 15
2026
Q1
$3.45M Buy
+3,750
New +$3.8M 1.6% 17
2025
Q4
Sell
-3,886
Closed -$2.97M 189
2025
Q3
$2.97M Sell
3,886
-44
-1% -$32.7K 1.45% 17
2025
Q2
$3.25M Hold
3,930
1.82% 15
2025
Q1
$3.25M Buy
3,930
+51
+1% +$42.4K 1.82% 15
2024
Q4
$2.99M Sell
3,879
-270
-7% -$224K 1.69% 15
2024
Q3
$3.68M Sell
4,149
-123
-3% -$111K 1.98% 16
2024
Q2
$3.87M Sell
4,272
-28
-0.7% -$22.4K 2.25% 11
2024
Q1
$3.35M Sell
4,300
-40
-0.9% -$28.5K 1.95% 13
2023
Q4
$2.53M Buy
4,340
+143
+3% +$83.5K 1.56% 19
2023
Q3
$2.25M Buy
4,197
+11
+0.3% +$5.67K 1.45% 21
2023
Q2
$1.96M Buy
4,186
+1
+0% +$419 1.23% 27
2023
Q1
$1.44M Buy
4,185
+1
+0% +$337 0.89% 38
2022
Q4
$1.53M Buy
4,184
+1
+0% +$355 0.96% 34
2022
Q3
$1.35M Sell
4,183
-18
-0.4% -$5.7K 0.94% 36
2022
Q2
$1.36M Buy
4,201
+185
+5% +$55.5K 0.88% 39
2022
Q1
$1.15M Buy
4,016
+948
+31% +$244K 0.62% 49
2021
Q4
$847K Sell
3,068
-58
-2% -$14.7K 0.45% 72
2021
Q3
$722K Sell
3,126
-12
-0.4% -$2.96K 0.42% 76
2021
Q2
$720K Sell
3,138
-14
-0.4% -$2.81K 0.4% 76
2021
Q1
$589K Sell
3,152
-82
-3% -$16K 0.34% 84
2020
Q4
$546K Sell
3,234
-114
-3% -$17K 0.36% 80
2020
Q3
$496K Sell
3,348
-658
-16% -$102K 0.36% 82
2020
Q2
$658K Buy
4,006
+2
+0% +$307 0.49% 65
2020
Q1
$555K Buy
4,004
+2
+0% +$275 0.49% 68
2019
Q4
$526K Buy
4,002
+22
+0.6% +$2.55K 0.35% 79
2019
Q3
$445K Buy
3,980
+3
+0.1% +$334 0.32% 82
2019
Q2
$441K Buy
3,977
+2
+0.1% +$236 0.31% 81
2019
Q1
$516K Buy
3,975
+2
+0.1% +$243 0.35% 75
2018
Q4
$460K Sell
3,973
-110
-3% -$12.3K 0.35% 75
2018
Q3
$438K Buy
4,083
+2
+0% +$200 0.31% 84
2018
Q2
$348K Buy
4,081
+2
+0% +$164 0.26% 94
2018
Q1
$316K Buy
4,079
+2
+0% +$161 0.25% 97
2017
Q4
$344K Buy
+4,077
New +$347K 0.26% 95

Other funds holding LLY

Murphy Middleton Hinkle & Parker's LLY Position: Q2 2026 in Review

Murphy Middleton Hinkle & Parker held its Eli Lilly (LLY) position steady in Q2 2026 at 3,750 shares worth $4.5M. The position accounts for 1.83% of the portfolio, ranked #15.

Murphy Middleton Hinkle & Parker first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. 923 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Murphy Middleton Hinkle & Parker held 3,750 shares of Eli Lilly worth $4.5M as of Q2 2026.
  • Murphy Middleton Hinkle & Parker left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 1.83% of Murphy Middleton Hinkle & Parker's portfolio in Q2 2026, its #15 holding.
  • Murphy Middleton Hinkle & Parker first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
  • 923 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q2 2026, filed 14 Jul 2026.